ZIMLABZim Laboratories Limited
Pharma · Drug Manufacturers - Specialty & Generic · NSE · as of 2026-10-26 (delayed ~30 min in market hours)
ZIM Laboratories Limited engages in the development, manufacture, and supply of generic pharmaceutical and nutraceutical products in India and internationally. It provides its products in pre- formulation intermediates and finished formulations in the oral solid dosage forms, such as pellets, taste-masked powders, directly compressible granules, tablets, capsules, dry syrup, and oral thin films. The company offers therapeutics in the areas of urology, gastroenterology, antibiotics, anti-infectives, cardiovascular, central nervous system, NSAIDs/pain analgesics, and vitamins and supplements. The company was founded in 1984 and is based in Nagpur, India.
Price & Volume
Loading chart…
Key Ratios
“—” means the figure isn't meaningful or isn't published for this company: ROE and Debt/Equity are undefined when shareholder equity is negative (check P/B — negative means negative equity), and DII/MF holding splits aren't provided by our current data source.
Active Pattern Signals
Why avoid
- • A bearish pattern is active and overall evidence is mixed
- • Profit growth: -52.0% YoY
- • ROE: 2.0%
- • RSI: 40
- • MACD: bearish
- • Double Top bearish signal (setup quality 68%)
Bull case
- • Revenue growth: 31.2% YoY
- • Debt/Equity: 0.43
- • Promoter holding: 71.2%
- • Price vs SMA200: above
Bear case
- • Profit growth: -52.0% YoY
- • ROE: 2.0%
- • RSI: 40
- • MACD: bearish
Key risks
- • Weak fundamentals — technical strength may not sustain
- • Profit growth: -52.0% YoY
- • ROE: 2.0%
Algorithmic analysis for research only — not SEBI-registered investment advice.
Trade Plan
Stop = 20-day support with a 2.5×ATR risk cap (ATR ₹8.88). Levels recompute on every data refresh. Position sizing and execution are yours — this is analysis, not advice.